Abstract:Epithelial-mesenchymal transition (EMT) contributes to tumor invasion, metastasis and drug resistance. AKT activation is key in a number of cellular processes. While many positive regulators for either EMT or AKT activation have been reported, few negative regulators are established. Through kinase cDNA screen, we identified brain-type creatine kinase (CKB or BCK) as a potent suppressor for both. As a ubiquitously expressed kinase in normal tissues, CKB is significantly downregulated in several solid cancer types. Lower CKB expression is significantly associated with worse prognosis. Phenotypically, CKB overexpression suppresses, while its silencing promotes, EMT and cell migration, xenograft tumor growth and metastasis of prostate cancer cells. AKT activation is one of the most prominent signaling events upon CKB silencing in prostate cancer cells, which is in line with prostate cancer TCGA data. EMT enhanced by CKB silencing is abolished by AKT inhibition. Mechanistically, CKB interacts with AKT and sequestrates it from activation by mTOR. We further elucidated that an 84aa fragment at C-terminus of CKB protein interacts with AKT's PH domain. Ectopic expression of the 84aa CKB fragment inhibits AKT activation, EMT and cell proliferation. Interestingly, molecular dynamics simulation on crystal structures of AKT and CKB independently demonstrates that AKT's PH domain and CKB's 84aa fragment establish their major interaction interface. In summary, we have discovered CKB as a negative regulator of EMT and AKT activation, revealing a new mode of their regulation . We have also demonstrated that CKB downregulation is a poor prognosticator, which is sufficient to promote prostate cancer progression.

Supplementary Figures 1-4 from Targeting IκB Kinase Β/nf-Κb Signaling in Human Prostate Cancer by a Novel IκB Kinase Β Inhibitor CmpdA

Supplementary Figures S1-S6 from Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Supplementary Figure 3 from Protein Kinase D As a Potential Chemotherapeutic Target for Colorectal Cancer

Supplementary Figures 1 - 12 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Regulation of FOXO3a/β-catenin/GSK-3β Signaling by 3,3′-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells.

Supplementary Figure 5 from Protein Kinase D3 (PKD3) Contributes to Prostate Cancer Cell Growth and Survival Through a PKCε/PKD3 Pathway Downstream of Akt and ERK 1/2

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Figures-1,2,3,4 and 5 from KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Supplementary Figures 1 Through 4 from Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells

Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Supplementary Figure Legends 1-5 from Protein Kinase D3 (PKD3) Contributes to Prostate Cancer Cell Growth and Survival Through a PKCε/PKD3 Pathway Downstream of Akt and ERK 1/2

Tumor-suppressive Microrna-497 Targets IKKβ to Regulate NF-κB Signaling Pathway in Human Prostate Cancer Cells.

Supplementary Figure from Blocking PI3K P110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer

Supplementary Figure 4 from p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis

IKK Inhibitor Suppresses Epithelial-Mesenchymal Transition and Induces Cell Death in Prostate Cancer.

Supplementary Figure 5B from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer

Supplementary Figures from Infiltrating Macrophages Promote Prostate Tumorigenesis Via Modulating Androgen Receptor-Mediated CCL4–STAT3 Signaling

CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation

Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Supplementary Figure S3 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplementary Information from &Lt;i>tmprss2-Erg</i> Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in <i>pten</i> and &Lt;i>tp53</i>-Mutated Prostate Cancer